CoreWeave vs Cassava Sciences Inc — how do they compare? CoreWeave trades at $83.73 (market cap $44.99B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: CoreWeave is far larger — about 1141.9× Cassava Sciences Inc's market cap, and CoreWeave is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 6 Days and Cassava Sciences Inc for 37 Days on average.
| CRWV | FLNA | |
|---|---|---|
Market Cap | $44.99B | $39.40M |
Volume | 41,993,776 | 759,018 |
Sector | Technology | Health |
52-Week High | $143.08 | $4.64 |
52-Week Low | $60.82 | $0.68 |
Typical Hold Time | 6 Days | 37 Days |
Enterprise Value | $91.06B | -$43.28M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →